Research Triangle Park, NC; In April 2005, Talecris, a subsidiary
of NPS BioTherapeutics Inc., acquired Bayer’s plasma products business for $590 million, but this did not include Bayer’s recombinant hemophilia products; Talecris also acquired the plasma fractionation and contract manufacturing facilities of Precision Pharma Services Inc.; Bayer continued to distribute plasma products for Talecris outside the U.S.; Talecris was formed with funding from Cerberus Capital Management and Ampersand Ventures; In June. 2010, Grifols acquired Talecris for $3.4 billion.
